Theravance Biopharma, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $350.2M | $344.7M |
| FY2017 | $223.7M | $115.2M | $89.0M |
| FY2018 | $454.4M | $-51.6M | $378.0M |
| FY2019 | $455.0M | $-223.8M | $58.1M |
| FY2020 | $619.2M | $-303.8M | $81.5M |
| FY2021 | $616.3M | $-338.6M | $90.0M |
| FY2022 | — | $441.8M | $298.2M |
| FY2023 | $0 | $213.0M | $39.5M |
| FY2024 | — | $175.5M | $37.8M |
| FY2025 | — | $296.7M | $167.8M |